NEW YORK, Nov. 13, 2013 /PRNewswire/ -- Pomerantz
Grossman Hufford Dahlstrom & Gross LLP is investigating claims
on behalf of investors of ViroPharma, Inc. ("ViroPharma" or the
"Company") (NASDAQ: VPHM) (ISIN: US9282411084) (CUSIP: 928241108)
concerning the proposed acquisition of ViroPharma by Shire Plc.
The investigation concerns whether the ViroPharma directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms of
the agreement, ViroPharma shareholders will receive $50.00 per share in cash for each share of
ViroPharma common stock. However, (i) the price to Revenue multiple
is below the average of comparable transactions; (ii) synergies may
not be fully reflected in offered price; and (iii) the current
Management team may stay on after the merger.
ViroPharma shareholders seeking more information about this
acquisition are advised to contact Robert
Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or
888-476-6529, ext. 237.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and San
Diego, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of defrauded
investors. See www.pomerantzlaw.com.
CONTACT:
Robert
Willoughby
Pomerantz Grossman Hufford Dahlstrom
& Gross LLP
212-661-1100 ext. 237
rswilloughby@pomlaw.com
SOURCE Pomerantz Grossman Hufford
Dahlstrom & Gross LLP